non-GALV-GP R- expressing oncolytic HSV

The non-GALV-GP R- expressing oncolytic HSV is a preclinical-stage oncolytic viral immunotherapy developed by Replimune as a parental or control construct for its RP1 platform. This genetically modified Herpes Simplex Virus type 1 (HSV-1) features deletions of the ICP34.5 and ICP47 genes to ensure tumor-selective replication and to enhance the presentation of tumor-associated antigens. The virus is engineered to express human granulocyte-macrophage colony-stimulating factor (GM-CSF) to stimulate a systemic anti-tumor immune response by recruiting and activating dendritic cells. Unlike the lead candidate RP1, this construct lacks the gibbon ape leukemia virus fusogenic membrane glycoprotein (GALV-GP R-) transgene, which is used to induce cell-cell fusion and enhance viral spread. In preclinical research, it serves as a benchmark to isolate the therapeutic contributions of the GALV-GP R- protein.